It works by producing a decrease in sympathetic outflow, resulting in a reduction in peripheral vascular resistance, renal vascular resistance, heart rate, and also blood pressure.

Guanfacine is similar to clonidine but is more selective for alpha2-adrenergic receptors, longer-acting, dosed once daily, and has less frequency and severity of rebound hypertension following the abrupt discontinuation.

Shire had proposed the trade name CONNEXYN? for the product.

With this submission, as well as the recent approval and launch of DAYTRANA?, the regulatory submission of SPD465, and the anticipated FDA response this October concerning NRP104, they have been successful in advancing their ADHD pipeline considerably, added Emmens.

It offers you the most extensive product information and up-to-date resources regarding this medication, including the related news articles, medical studies, an image library and all the necessary information on dosage and side effects.

Whether you are an average consumer or a pharma professional, you can now find out everything you need to know about guanfacine on this reference site, as well as take part in our open discussion forum by sharing your own knowledge and experience with people who are using this medication.

This unique site also provides you with inside industry news on which companies or organizations are playing a very important role in its research, development, production and promotion. It is your one-stop site for a total guanfacine understanding.